iXCells Taps Steve Smith as CEO

iXCells Biotechnologies, a provider of human cell-based solutions and custom iPSC services, has appointed Steve Smith as CEO.

Previously CCO, Smith will lead the Company to advance execution and delivery of iXCells’ bespoke human-derived iPSC preclinical services as demand increases for scalable, high-quality, and human relevant preclinical models.

“Steve’s appointment marks a pivotal moment for iXCells,” said Alex Gulotta, Principal at Great Point Partners. “His strategic vision and deep expertise in iPSC technologies and human cell-based research are exactly what we need to accelerate our mission. With initiatives like iPSCore and Project Mosaic already gaining traction under his leadership, I’m confident that Steve will guide iXCells to new heights of scientific innovation and impact.”

Experience

Smith has over 25 years’ experience in the life sciences industry, with a career spanning senior commercial leadership roles across global life science tools and service organizations. Holding leadership positions at Thermo Fisher and Abcam, including North American Sales Leader and Vice President of Cell Lines, Smith most recently served as CCO at seqWell, a provider of genomic library and multiplexing workflow solutions. His appointment as CEO marks a significant milestone for iXCells as the Company transitions into its next phase of growth, supporting larger, more complex preclinical programs and expanding multi-study collaborations with biotech, pharmaceutical, academic, and CRO partners.

Smith said: “I am excited to lead iXCells through this next stage of growth, expanding our iPSCore end to end services, delivering actionable results in ongoing scientific partnerships, and providing customers with the consistency, scale, and collaboration required to advance complex discovery programs to enable the development of novel therapeutics for rare and complex diseases.”